Searching for new cardiovascular drugs: Towards improved systems for drug screening?

Expert Opinion on Drug Discovery

Volumn 6, Issue 11, 2011, Pages 1155-1170

  Silvester, Nicole C ^a   George, Christopher H ^a  

^a CARDIFF UNIVERSITY SCHOOL OF MEDICINE   (United Kingdom)

Author keywords

assay; cardiovascular; drugs; platform; screening; systems; technology

Indexed keywords

CARDIOVASCULAR AGENT;

CARDIOVASCULAR DISEASE; DRUG ACTIVITY; DRUG EFFICACY; DRUG MECHANISM; DRUG RESEARCH; DRUG SAFETY; DRUG SCREENING; HUMAN; NONHUMAN; PATENT; PRIORITY JOURNAL; REVIEW; TECHNOLOGY;

EID: 80755130608     PISSN: 17460441     EISSN: 1746045X     Source Type: Journal    
DOI: 10.1517/17460441.2011.625652     Document Type: Review

References (121)

1. George CH, Barberini-Jammaers SR, Muller CT. Refocussing therapeutic strategies for cardiac arrhythmias: defining viable molecular targets to restore cardiac ion flux. Expert Opin Ther Patents 2008;18:1-19 (Pubitemid 351291795)
2. Available from: http://www.fda.gov/ Drugs/default.htm.
3. Savelieva I, Camm J. Anti-arrhythmic drug therapy for atrial fibrillation: current anti-arrhythmic drugs, investigational agents and innovative approaches. Europace 2008;10:647-65 (Pubitemid 351775283)
4. Landmesser U, Wollert KC, Drexler H. Potential novel pharmacological therapies for myocardial remodelling. Cardiovasc Res 2009;81:519-27
5. Nattel S, Carlsson L. Innovative approaches to anti-arrhythmic drug therapy. Nat Rev Drug Disc 2006;5:1034-49 (Pubitemid 44835130)
6. Mason PK, DiMarco JP. New pharmacological agents for arrhythmias. Circ Arrhythmia Electrophysiol 2009;2:588-97
7. Mukherjee D, Nissen SE, Topol EJ. Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA 2001;286:954-9 (Pubitemid 33010342)
8. Bowe C. Vioxx storm to have lasting effects. Financial Times 2007; November 12.
9. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007;356:2457-71 (Pubitemid 46919772)
10. Masoudi FA. Improving drug safety surveillance: lessons from rosiglitazone. Circ Cardiovasc Qual Outcomes 2010;3:444-6
11. Chong CR, Sullivan DJ. New uses for old drugs. Nature 2007;448:645-6 (Pubitemid 47236844)
12. Available from: http://www.uspto.gov/.
13. Available from: http://www.epo.org/ searching/free/espacenet.html.
14. Netzer R, Pongs O. Novel tension-dependent potassium channel and the use thereof in the development of new therapeutic agents. EP1102847; 2008
15. Milting H, Lukas N, Klauke B, et al. Composite polymorphisms in the ryanodine receptor 2 gene associated with arrhythmogenic right ventricular cardiomyopathy. Cardiovasc Res 2006;71:496-505 (Pubitemid 44131528)
16. Poelzing S, Forleo C, Samodell M, et al. SCN5A polymorphism restores trafficking of a Brugada syndrome mutation on a separate gene. Circulation 2006;114:368-75
17. Farkas AS, Nattel S. Minimizing repolarization-related proarrhythmic risk in drug development and clinical practice. Drugs 2010;70:573-603
18. Nattel S, Duker G, Carlsson L. Model systems for the discovery and development of antiarrhythmic drugs. Prog Biophys Mol Biol 2008;98:328-39
19. Moller C, Slack M. Impact of new technologies for cellular screening along the drug value chain. Drug Discov Today 2010;15:384-90
20. Available from: http://www.ema.europa. eu/docs/en-GB/document-library/ Scientific-guideline/2009/09/ WC500002841.pdf
21. Available from: http://www.fda.gov/ drugs/guidancecomplianceregulatory information/guidances/default.htm 2011.
22. Lindgren S, Bass AS, Briscoe R, et al. Benchmarking safety pharmacology regulatory packages and best practice. J Pharmacol Toxicol Methods 2008;58:99-109
23. Lu HR, Vlaminckx E, Hermans AN, et al. Predicting drug-induced changes in QT interval and arrhythmias: QT-drugs point to gaps in the ICHS7B guidelines. Br J Pharmacol 2008;154:1427-38
24. Witchel HJ, MIlnes JT, Mitcheson JS, et al. Troubleshooting problems with in vitro screening of drugs for QT interval prolongation using HERG K+ channels expressed in mammalian cell lines and xenopus oocytes. J Pharmacol Toxicol Methods 2002;48:65-80 (Pubitemid 37288933)
25. Maher MP, Gonzalez JE III. High throughput method and system for screening candidate compounds for activity against target ion channels. US7176016; 2007
26. Vasylyev DV, Merrill TL, Bowlby MR, et al. Perfusion system and apparatus for automated multi-channel patch-clamp recordings utilizing inside-out whole-cell configuration. US7465558; 2008
27. Yan G-X. Methods for screening compounds for proarrhythmic risk and antiarrhythmic efficacy. US7396524; 2008
28. Owen DG, Byrne NG. High throughput screen. EP1621888; 2009
29. Adorante JS, Ehring GR. High-throughput screen for identifying selective persistent sodium channels channel blockers. US7754440; 2010
30. Brown AM, Ficker E, Wible BA. High throughput assay systems and methods for identifying agents that alter expression of cellular proteins. US7678548; 2010
31. Mendrick DL, Porter MW, Johnson KR, et al. Molecular cardiotoxicology modeling. US7447594; 2008
32. James JF, Hewett TE, Robbins J. Cardiac physiology in transgenic mice. Circ Res 1998;82:407-15 (Pubitemid 28117321)
33. Redfern WS, Carlsson L, Davis AS, et al. Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development. Cardiovasc Res 2003;58:32-45 (Pubitemid 36351620)
34. Witchel HJ. Drug-induced hERG block and long QT syndrome. Cardiovasc Ther 2011;29:251-9
35. Haverkamp W, Breithardt G, Camm AJ, et al. The potential for QT prolongation and proarrhythmia by non-antiarrhythmic drugs: clinical and regulatory implications. Eur Heart J 2001;3(Suppl K):81-9
36. Moller C. Keeping the rhythm: hERG and beyond in cardiovascular safety pharmacology. Expert Rev Clin Pharmacol 2010;3:321-9
37. Kowey PR, Malik M. The QT interval as it relates to the safety on non-cardiac drugs. Eur Heart J 2007;9(Suppl G):G3-8
38. Peal DS, Mills RW, Lynch SN, et al. Novel chemical suppressors of long QT syndrome identified by an in vivo functional screen. Circulation 2011;123:23-30
39. Roth BL, Sheffler DJ, Kroeze WK. Magic shotguns versus magic bullets: selectively non-selective drugs for moods disorders and schizophrenia. Nat Rev Drug Disc 2004;3-353-9 (Pubitemid 38499762)
40. Rosen MR, Robinson RB, Cohen IS, et al. High throughput biological heart rate monitor that is molecularly determined. US7122307; 2006
41. Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 2006;126:663-76 (Pubitemid 44233629)
42. Takahashi H, Tanabe K, Ohnuki M, et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 2007;131:861-72 (Pubitemid 350138099)
43. Yu J, Vodyanik MA, Smuga-Otoo K, et al. Induced pluripotent stem cell lines derived from human somatic cells. Science 2007;318:1917-20
44. Park I-H, Zhao R, West JA, et al. Reprogramming of human somatic cells to pluripotency with defined factors. Nature 2008;451:141-6
45. Zhang J, Wilson GF, Soerens AG, et al. Functional cardiomyocytes derived from human induced pluripotent stem cells. Circ Res 2009;104:e30-41
46. Not assigned. Embryonic stem cells produced via embryo destruction are not patentable. Nat Rev Drug Disc 2011;10:330
47. Cyranoski D. Japan fast-tracks stem-cell patent. Nature 2008;455:269
48. Cyranoski D. Japan ramps up patent effort to keep iPS lead. Nature 2008;453:962-3 (Pubitemid 351871702)
49. Webb S. The gold rush for induced pluripotent stem cells. Nat Biotechnol 2009;27:977-9
50. Yamanaka S. Method for producing induced pluripotent stem cell. JP2008283972; 2008
51. Sakurada K, Masaki H, Ishikawa T. Human pluripotent stem cells and their medical use. GB2450603; 2010
52. Jaenisch R, Hochedlinger K. Methods for reprogramming somatic cells. US7682828; 2010
53. Thomson JA, Kamp TJ, Ma Y, et al. Functional cardiomyocytes from human embryonic stem cells. US7611852; 2009
54. Xu C, Gold JD. Process for making transplantable cardiomyocytes from human embrynonic stem cells. US7732199; 2010
55. Murry CE, Laflamme MA. Formulation to improve survival of transplanted cells. US7875451; 2011
56. Zon LI, Davidson AJ, Daley GQ. Method of enhancing proliferation and/ or hematopoietic differentiation of stem cells. US7427603; 2008
57. Kaji K, Norrby K, Paca A, et al. Virus-free induction of pluripotency and subsequent excision of reprogramming factors. Nature 2009;458:771-5
58. Kim D, Kim C-H, Moon J-I, et al. Generation of human induced pluripotent stem cells by direct delivery of reprogramming proteins. Cell Stem Cell 2009;4:472-6
59. Chien KR. Regenerative medicine and human models of human disease. Nature 2008;453:302-5 (Pubitemid 351693135)
60. Passier R, van Laake LW, Mummery CL. Stem-cell-based therapy and lessons from the heart. Nature 2008;453:322-9 (Pubitemid 351693138)
61. Braam SR, Passier R, Mummery CL. Cardiomyocytes from human pluripotent stem cells in regenerative medicine and drug discovery. Trends Pharm Sci 2009;30:536-45
62. Kim K, Doi A, Wen B, et al. Epigenetic memory in induced pluripotent stem cells. Nature 2010;467:285-90
63. Zwaka TP. Troublesome memories. Nature 2010;437:280-1
64. Gore A, Li Z, Fung H-L, et al. Somatic coding mutations in human induced pluripotent stem cells. Nature 2011;471:63-7
65. Lister R, Pelizzola M, Kida YS, et al. Hotspots of aberrant epigenomic reprogramming in human induced pluripotent stem cells. Nature 2011;471:68-73
66. McNeish J. Embryonic stem cells in drug discovery. Nat Rev Drug Discov 2004;3:70-80 (Pubitemid 38088699)
67. Pouton C, Haynes JM. Embryonic stem cells as a source of models for drug discovery. Nat Rev Drug Discov 2007;6:605-16 (Pubitemid 47202486)
68. Dick E, Rajamohan D, Ronksley J, et al. Evaluating the utility of cardiomyocytes from human pluripotent stem cells for drug screening. Biochem Soc Trans 2010;38:1037-45
69. Yokoo N, Baba S, Kaichi S, et al. The effects of cardioactive drugs on cardiomyocytes derived from human induced pluripotent stem cells. Biochem Biophys Res Commun 2009;387:482-8
70. Laflamme MA, Chen KY, Naumova AV, et al. Cardiomyocytes derived from human embryonic stem cells in pro-survival factors enhance function of infarcted rat hearts. Nat Biotechnol 2007;25:1015-24 (Pubitemid 47517637)
71. Dambrot C, Passier R, Atsma D, et al. Cardiomyocyte differentiation of pluripotent stem cells and their use as cardiac disease models. Biochem J 2011;434:25-35
72. Moretti A, Bellin M, Welling A, et al. Patient-specific induced pluripotent stem-cell models for Long-QT syndrome. N Engl J Med 2010;363:1397-409
73. Itzhaki I, Maizels L, Huber I, et al. Modelling the long QT syndrome with induced pluripotent stem cells. Nature 2011;471:225-9
74. Matsa E, Rajamohan D, Dick E, et al. Drug evaluation in cardiomyocytesderived from human induced pluripotent stem cells carrying a long QT syndrome type 2 mutation. Eur Heart J 2011;32:952-62
75. Yazawa M, Hseuh B, Jia X, et al. Using induced pluripotent stem cells to investigate cardiac phenotypes in Timothy Syndrome. Nature 2011;471:230-4
76. Samuels MA. The Brain-Heart connection. Circulation 2007;116:77-84 (Pubitemid 47016249)
77. Ieda M, Fu J-D, Delgado-Olguin P, et al. Direct reprogamming of fibroblasts into functional cardiomyocytes by defined factors. Cell 2010;142:375-86
78. Efe JA, Hilcove S, Kim J, et al. Conversion of mouse fibroblasts into cardiomyocytes using a direct reprogramming strategy. Nat Cell Biol 2011;13:215-22
79. Angert D, Berretta RM, Kubo H, et al. Repair of the injured adult heart involves new myocytes potentially derived from resident cardiac stem cells. Circ Res 2011;108:1226-37
80. Kajstura J, Urbanek K, Perl S, et al. Cardiomyogenesis in the adult human heart. Circ Res 2010;107:305-15
81. Hansen A, Eder A, Bonstrup M, et al. Development of a drug screening platform based on engineered heart tissue. Circ Res 2010;107:35-44
82. Tandon N, Cannizzaro C, Chao P-HG, et al. Electrical stimulation systems for cardiac tissue. Nat Protocols 2009;4:155-73
83. Zimmerman WH, Eschenhagen T. Multiloop engineered heart muscle tissue. EP1963489; 2010
84. Madry H, Vunjak-Novakovic G, Trippel SB, et al. Tissue engineering enhanced by the transfer of a growth factor gene. US7252982; 2007
85. Kang G, Giovannone SF, Liu N, et al. Purkinje cells from RyR2 mutant mice are highly arrhythmogenic but responsive to targeted therapy. Circ Res 2010;107:512-19
86. Coronel R, Wilms-Schopman JG, Janse MJ. Anti- or profibrillatory effects of Na+ channel blockade depend on the site of application relative to gradients in repolarization. Front Physiol 2010;1:1-9
87. Sicouri S, Carlsson L, Antzelevitch C. Electrophysiologic and antiarrhythmic effects of AZD1305 in canine pulmonary vein sleeves. J Pharm Exp Ther 2010;334:255-9
88. Hondeghem LM, Carlsson L, Duker G. Instability and triangulation of the action potential predict serious proarrhythmia, but action potential duration prolongation is antiarrhythmic. Circulation 2001;103:2004-13 (Pubitemid 32322230)
89. Bassingthwaighte J, Hunter P, Noble D. The cardiac physiome: perspectives for the future. Exp Physiol 2009;94.5:597-605
90. Patten RD, Hall-Porter MR. Small animal models of heart failure: development of novel therapies, past and present. Circ Heart Fail 2009;2:138-44
91. Brunner M, Peng X, Liu G-X, et al. Mechanisms of cardiac arrhythmias and sudden death in transgenic rabbits with long QT syndrome. J Clin Invest 2008;118:2246-59 (Pubitemid 351872342)
92. Koren G, Peng X, Mathur R, et al. Animal models of long QT syndrome and uses thereof. US7718846; 2010
93. MacRae CA, Milan DJ, Burns CG, et al. Zebrafish assay. US7465848; 2008
94. Rubinstein AL. Zebrafish assays for drug toxicity screening. Expert Opin Drug Metab Toxicol 2006;2:231-40 (Pubitemid 46372366)
95. Milan DJ, Peterson TA, Ruskin JN, et al. Drugs that induce repolarization abnormalities cause bradycardia in zebrafish. Circulation 2003;107:1355-8 (Pubitemid 36350731)
96. Hassel D, Scholz EP, Trano N, et al. Deficient zebrafish ether-a-go-go-related gene channel gating causes short-QT syndrome in zebrafish reggae mutants. Circulation 2008;117:866-75 (Pubitemid 351272584)
97. Sehnert A, Stainier DYR. A window to the heart: can zebrafish mutants help us understand heart disease in humans? Trends Genet 2002;18:491-4 (Pubitemid 35287017)
98. Available from: http://www.sanger.ac.uk/ Projects/D-rerio/mutres/.
99. Chan JNY, Nislow C, Emili A. Recent advances and method development for drug target identification. Trends Pharm Sci 2009;31:82-8
100. Keiser MJ, Setola V, Irwin JJ, et al. Predicting new molecular targets for known drugs. Nature 2009;462:175-81
101. Agarwal P, Searls DB. Can literature analysis identify innovation drivers in drug discovery. Nat Rev Drug Discov 2009;8:865-78
102. Newton-Cheh C, Eijgelsheim M, Rice KM, et al. Common variants at ten loci influence QT interval duration in the QTGEN Study. Nat Genet 2009;41:399-406
103. Pfeufer A, Sanna S, Arking DE, et al. Common variants at ten loci modulate the QT interval duration in the QTSCD Study. Nat Genet 2009;41:407-14
104. Sotoodehnia N, Isaacs A, de Bakker PIW, et al. Common variants in 22 loci are associated with QRS duration and cardiac ventricular conduction. Nat Genet 2010;42:1068-76
105. Nordin C. The case for hypoglycaemia as a proarrhythmic event: basic and clinical evidence. Diabetologia 2010;53:1552-61
106. Ratner M. Pfizer reaches out to academia- again. Nat Biotechnol 2010;29:3-4
107. Hohnloser SH, Crijns HJGM, van Eickels M, et al. Effect of dronedarone on cardiovascular events in atrial fibrillation. N Engl J Med 2009;360:668-78
108. Kober L, Torp-Pedersen C, McMurray JJV, et al. Increased mortality after dronedarone therapy for severe heart failure. N Engl J Med 2008;358:2678-87 (Pubitemid 351860860)
109. Watanabe H, Chopra N, Laver D, et al. Flecainide prevents catecholaminergic polymorphic ventricular tachycardia in mice and humans. Nat Med 2009;15:380-3
110. Echt DS, Liebson PR, Mitchell LB, et al. Mortality and morbidity in patient receiving encainide, flecainide, or placebo. The cardiac arrhythmia suppression trial. N Engl J Med 1991;324:781-4
111. Drici M-D, Clement N. Is gender a risk factor for adverse drug reactions? The example of drug-induced long QT syndrome. Drug Saf 2001;24:575-85
112. Roden DM. Proarrhythmia as a pharmacogenomic entity: a critical review and formulation of a unifying hypothesis. Cardiovasc Res 2005;67:419-25 (Pubitemid 41019549)
113. Liggett SB, Cresci S, Kelly RJ, et al. A GRK5 polymorphism that inhibitsβ-adrenergic receptor signaling is protective in heart failure. Nat Med 2008;14:510-17 (Pubitemid 351655214)
114. Sotoodehnia N, Siscovick DS, Vatta M, et al. B2-adrenergic receptor genetic variants and risk of sudden cardiac death. Circulation 2006;113:1842-8 (Pubitemid 43739395)
115. Keating MT, Splawski I. Common polymorphism in SCN5A implicated in drug-induced cardiac arrhythmia. US7208273; 2007
116. Hamburg MA, Collins FS. The path to personalized medicine. N Engl J Med 2010;363:301-4
117. Brouillette J, Rivard K, Lizotte E, et al. Sex and strain differences in adult mouse cardiac repolarization: importance of androgens. Cardiovasc Res 2005;65:148-57 (Pubitemid 40038487)
118. Mason SA, MacLeod KT. Cardiac action potential duration and calcium regulation in males and females. Biochem Biophys Res Commun 2009;388:565-70
119. Shah AP, Siedlecka U, Gandhi A, et al. Genetic background affects function and intracellular calcium regulation of mouse hearts. Cardiovasc Res 2010;87:683-93
120. Jack A. Pharmaceuticals: perils for pill pushers. Financial Times 2010; Sept 21 2010.
121. Watkins PB. Drug safety sciences and the bottleneck in drug development. Clin Pharmacol Ther 2011;89:788-90